medpagetoday.com
Risankizumab Tops Competitor for Clinical Remission in Moderate-to-Severe CD
Cure8 flagged this item because the article title and available source metadata connect it to Risankizumab, IL-23 inhibitor, and Medications. We do not yet have enough reliable article text to summarize the details.
This may be most useful for Clinicians and Patients On Biologics following Risankizumab, IL-23 inhibitor, and Medications.
What To Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a clinical trial phase 3 related to Risankizumab, IL-23 inhibitor, and Medications. Use the original source link for the full details.
Trial findings can depend on who was enrolled, what outcomes were measured, and how long people were followed. The original source has the study details.
